Sociedad Americana de Hirudoterapia

Secondary Trigeminal Neuralgia (Investigational Adjunct)

Highly investigational adjunct for secondary trigeminal neuralgia after MRI evaluation; carbamazepine and oxcarbazepine remain first-line; microvascular decompression for refractory cases.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?
Not FDA-cleared for trigeminal neuralgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for secondary trigeminal neuralgia is investigational.
¿Qué evidencia existe?
Tier C (investigational). Only case reports; there are no randomized controlled trials. Evidence-based therapy for trigeminal neuralgia: carbamazepine or oxcarbazepine as first-line (AAN-endorsed), with lamotrigine, baclofen, or gabapentin as alternatives. Microvascular decompression surgery in selected fit patients (long-term pain relief >70 percent). Gamma knife radiosurgery and percutaneous procedures (glycerol injection, balloon compression, radiofrequency thermocoagulation) for medically refractory disease. Secondary causes (multiple sclerosis, tumor) require treatment of the underlying disease.
Riesgos principales
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Trigger of acute trigeminal pain attack at bite locations on the face
  • Local skin infection or, rarely, Aeromonas infection on the face
  • Allergic reaction to leech saliva (uncommon)
  • Post-inflammatory hyperpigmentation or scarring on the face
  • Risk if leech placed too close to the eye or ophthalmic branch
  • Delay of carbamazepine, microvascular decompression, or workup for secondary causes
  • Risk of missed multiple sclerosis or tumor as cause of secondary trigeminal neuralgia
Quién no debería considerar esto
  • Patients who have not been worked up for multiple sclerosis or tumor (MRI required)
  • Patients with active herpes zoster of the trigeminal nerve
  • Patients with eye involvement or first-division (V1) trigeminal pain (specialty care)
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not tried carbamazepine or oxcarbazepine
  • Patients with darker Fitzpatrick skin types at high PIH risk on the face
Qué preguntar a su clínico
  • Have I had an MRI brain to rule out multiple sclerosis or tumor?
  • Have I tried carbamazepine or oxcarbazepine at therapeutic doses?
  • Am I a candidate for microvascular decompression or gamma knife radiosurgery?
  • What evidence specifically supports leech therapy for trigeminal neuralgia?
  • What is the risk of triggering a pain attack with facial leech bites?
  • Are leeches from an FDA-registered supplier and used only once?
  • What is the cost and is it covered by insurance? (typically not covered)
Cuándo buscar atención urgente
  • New double vision, eye pain, or vision loss (cranial nerve or eye involvement)
  • Sudden severe facial weakness or numbness (possible stroke or tumor progression)
  • New limb weakness, balance problems, or vision changes (possible MS exacerbation)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Qué NO significa esto

  • This is NOT FDA-cleared for trigeminal neuralgia.
  • Case reports do NOT establish efficacy versus carbamazepine, microvascular decompression, or gamma knife radiosurgery.
  • It does NOT replace MRI workup for secondary causes (MS, tumor) in secondary trigeminal neuralgia.
  • It does NOT substitute for evidence-based pharmacologic or surgical therapy.
  • It does NOT mean facial leech application is safe — pigment changes and scarring are facial-cosmetic concerns.

Clinical Profile

Category
neurological
ICD-10
G50.0
Safety tier
high

Evidence Summary

Trigeminal neuralgia (TN) involves paroxysmal lancinating facial pain in trigeminal distribution. Classical TN is often associated with neurovascular compression at the root entry zone; secondary TN may relate to multiple sclerosis or tumor. Per AAN and EFNS guidance, first-line therapy is carbamazepine or oxcarbazepine; surgical options for refractory cases include microvascular decompression, percutaneous procedures, and stereotactic radiosurgery. No controlled clinical trial of hirudotherapy for trigeminal neuralgia has been published; any use is investigational and mechanistic only. MRI evaluation must be completed before any adjunctive consideration.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Krashenyuk AI (2010)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • MRI not completed (intracranial mass or MS demyelination must be excluded)
  • Facial placement directly on trigeminal distribution
  • Placement over temporal artery (risk of arterial bleeding)
  • Discontinuation of first-line pharmacotherapy
  • Active dental or sinus pathology mimicking TN

Related Conditions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Secondary Trigeminal Neuralgia (Investigational Adjunct) — Hirudotherapy Evidence | ASH